Aquinox sitting pretty ahead of Phase 2a data
With a strong investor syndicate of venture capital funds, closely held Aquinox Pharmaceuticals of Vancouver is in an enviable position ahead of the release, in June, of Phase 2a clinical trial results...
View ArticleBrainsway reports positive smoking cessation results
Brainsway (TASE:BRIN) has reported additional positive final results in a clinical trial at Israel’s Be’er Ya’akov Mental Health Center to assess the efficacy of its Deep TMS device in inducing smoking...
View ArticleIn conversation with Bing Yao
Bing Yao As an SVP of AstraZeneca’s (NYSE:AZN) MedImmune unit, Bing Yao heads the Respiratory, Inflammation & Autoimmunity (RIA) Innovative Medicines unit at MedImmune, leading a team dedicated to...
View ArticleInogen POCs represent paradigm shift in oxygen therapy
Inogen (NASDAQ:INGN) is continuing to convert patients with lung disease from bulky oxygen tanks that need to be refilled every two weeks to its lightweight, portable oxygen concentrator (POC) that...
View ArticleMediciNova to release asthma and COPD trial results in Q2
MediciNova (NASDAQ:MNOV; OSE:4875) expects to release results from two clinical trials in the current second quarter with its lead drug candidate, MN-221, opening the door to a possible pivotal trial....
View ArticleLeerink starts Theravance Biopharma at outperform
Leerink has initiated coverage of Theravance Biopharma (NASDAQ:TBPH) with an “outperform” rating and $26 price target. The stock closed at $18.10 on Wednesday. Theravance was formed in 2014 via a spin...
View ArticleHCW starts Aviragen Therapeutics at buy
H.C. Wainwright launched coverage of Aviragen Therapeutics (NASDAQ:AVIR) with a “buy” rating and price target of $5. The stock closed at $1.43 on Tuesday. Aviragen is a developing three direct-acting...
View Article
More Pages to Explore .....